Advertisement

Topics

Companies Related to "Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma" [Most Relevant Company Matches] RSS

03:50 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma" found in our extensive corporate database of over 50,000 company records.

Showing "Genetic Study Patients With Acute Myeloid Leukemia Acute" Companies 1–25 of 4,800+

Extremely Relevant

Rasna Therapeutics , Inc.

Rasna Therapeutics, Inc. is a biotechnology company focused primarily on the high unmet need that exists for leukemias. Rasna’s primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients. The company has a balanced...


Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the high unmet need that exists for leukemias. Rasna’s primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients. The comp...

Update Pharma Inc.

Update Pharma Inc. is developing UPI-928, an agent developed in the 1980’s by Lederle Laboratories in 44 phase 1, 2 and 3 clinical trials, including 33 clinical trials at the National Cancer Institute. Despite an acceptable safety database of over 2,000 treated patients, over 70 peer reviewed clinical publications that demonstrated efficacy in leukemi...


Iterion Therapeutics

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Tegavivint demonstrate...

DCPrime

DCPrime develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne™. DCOne-based dendritic cell vaccines, in some indications loaded with cancer antigens for targeted treatment, are used as standardized, therapeutic products. The platform combines the power of den...

Formula Pharmaceuticals Inc.

Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01 is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in acute myeloid leukemia (AML) and other canc...

Imago BioSciences

Imago BioSciences is a clinical-stage, venture-backed pharmaceutical company focused on improving the management of proliferative diseases of the bone marrow and modulation of the immune system. The company is currently focused on neoplastic diseases of the bone marrow including acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibr...

Formula Pharmaceuticals

Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01, is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in acute myeloid leukemia (AML) and other can...

Formula Pharmaceuticals, Inc.

Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula’s lead product candidate, FPI-01, is a first-in-class immunotherapeutic in clinical development for the maintenance of first-remission in acute myeloid leukemia (AML) and other can...

EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in ...

Relevant

Cigna Corporation and Piedmont Healthcare

Piedmont Healthcare is a private, not-for-profit organization that serves nearly two million patients primarily in North Georgia communities but also across the state. The six hospitals include Piedmont Atlanta Hospital, a 529-bed acute-care hospital in Buckhead; Piedmont Fayette Hospital, a 172-bed, acute-care community hospital in Fayetteville; Piedmont ...

Promise Healthcare, Inc.

Based in Boca Raton, Florida, Promise Healthcare is one of the largest long-term acute care (LTAC) hospital organizations in the country. With more than 2,000 staff members and 13 hospitals nationwide, Promise Hospitals utilize an interdisciplinary approach to healing and wellness. Promise’s distinctive LTAC environment provides acute medical care and ...

Ischemix, Inc.

Ischemix is a privately-held, clinical-stage pharmaceutical company developing novel cytoprotective compounds for the prevention and treatment of serious diseases and conditions. The initial focus of the Company is the prevention of acute kidney injury and cardiac injury in patients undergoing cardiac catheterization procedures. Ischemix’ lead product...

MaaT Pharma

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leuk...

Promise Healthcare

Headquartered in Boca Raton, Florida, Promise Healthcare, Inc. (www.promisehealthcare.com) is one of the largest long-term acute care (LTAC) hospital organizations in the country. With more than 5,000 staff members and 19 health care facilities nationwide, Promise hospitals utilize an interdisciplinary approach to healing and wellness. Promise’s distinctive ...

Regenacy Pharmaceuticals

Regenacy Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment peripheral neuropathies, cognitive disorders, hemoglobinopathies and oncology indications. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy ...

Ocera Therapeutics, Inc.

Ocera Therapeutics, based in San Diego, California, USA, is a privately held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic liver diseases and a broad range of gastrointestinal disorders. In addition to AST-120, Ocera is developing OCR-002, an ammonia detoxification agent, for the treatment of hospitalized patients wit...

Regenacy Pharmaceuticals, LLC

Regenacy Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of peripheral neuropathies, ciliopathic/polycystic diseases, hemoglobinopathies, cognitive disorders and oncology indications. The company’s selective inhibition technology provides superior safety profi...

Aravive Biologics, Inc.

Aravive Biologics is a privately held, late pre-clinical stage biopharmaceutical company developing novel, highly selective cancer therapies that treat serious malignancies while sparing normal healthy cells. The company’s lead program is focused on the GAS6/AXL pathway, where activation appears to play a critical role in multiple types of cancer mali...

Xenetic Biosciences Inc.

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next-generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs, and OncoHist® for the development of novel oncolog...

Promise Healthcare Group, LLC

Headquartered in Boca Raton, Florida, Promise Healthcare Group, LLC operates two operating subsidiaries, Promise Healthcare, Inc. and Success Healthcare, LLC, one of the largest long-term and short-term acute care hospital organizations in the country. With more than 5,000 staff members and 24 health care facilities nationwide, Promise and Success hospital...

Xenetic Biosciences, Inc.

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology...

naviHealth, Inc.

naviHealth partners with health plans, health systems, accountable care organizations and post-acute providers to manage the entire continuum of post-acute care. The Company utilizes evidence-based protocols and technology-enabled services to optimize care and align all stakeholders. naviHealth has more than 12 years of experience managing post-acute care ...

Colorado Acute Long Term Hospital

Colorado Acute Long Term Hospital is a 63-bed hospital in Denver, Colorado, providing high acuity care for patients requiring intensive medical, nursing, respiratory and therapy services. The hospital focuses on meeting the needs of all its partners in care, including the referring physician, the patient and the patient's family. Renovated in early 2008 to include all private rooms, the hospital o...

ALung Technologies, Inc.

ALung Technologies, Inc. is commercializing artificial lung devices for the treatment of acute and chronic respiratory disorders. The company's Hemolung System, designed to replace or supplement the use of ventilators for patients with acute respiratory failure, is scheduled to begin clinical trials in the fall of 2009. Learn more about ALung and Hemolung at www.alung.com.


More From BioPortfolio on "Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks